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Abstract: A model-based insulin sensitivity parameter (SI) is often used in glucose-insulin system 
models to define the glycaemic response to insulin. As a parameter identified from clinical data, insulin 
sensitivity can be affected by blood glucose (BG) sensor error and measurement timing error, which can 
subsequently impact analyses or glycaemic variability during control. This study assesses the impact of 
both measurement timing and BG sensor errors on identified values of SI and its hour-to-hour variability 
within the ICING-type glucose-insulin system models. 
Retrospective clinical data was used from 270 patients of the Christchurch Hospital intensive care unit 
(ICU). An error model was created for the Arkray Super-Glucocard II glucometer used in Christchurch 
from manufacturer supplied data. Timing error was estimated from recent, computerised clinical data. 
Monte Carlo analysis was used to quantify the impact of these random errors by identifying SI profiles 
from data incorporating errors and comparing them to the ‘true’ SI profile (without additional errors) at 
each patient hour. To consolidate comparisons over the n = 100 Monte Carlo simulations, the width of 
the interquartile range (IQR) was used for percentage difference from the true SI level and for percentage 
hour-to-hour variability. 
The results of the study show that timing errors in isolation have little clinically significant impact on 
identified SI level or variability. The clinical impact of changes to SI level induced by combined sensor 
and timing errors is likely to be limited during glycaemic control. Identified values of SI were typically 
within 12% of the true value when influenced by both sources of error. In contrast, for variability, 95% of 
patient hours had an IQR of 34.9%, indicating that for half the simulations the hour-to-hour variability of 
SI was within ±17.5%.  
The results of this study indicate that the impact of sensor or timing errors on SI level is unlikely to be 
clinically significant. The effects are probably overshadowed by physiological factors arising from the 
critical condition of the patients or other under-modelled or un-modelled dynamics. In contrast, the 
impact of errors on hour-to-hour SI variability is more pronounced and may impact the way the SI 
parameter is utilised for control and analysis 
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1. INTRODUCTION 
Physiological glucose-insulin system models typically rely on 
some form of insulin sensitivity parameter to characterise the 
patient-specific glycaemic response to exogenous insulin (Lin 
et al., 2011, Hovorka et al., 2008). This model-based insulin 
sensitivity parameter (SI) is identified for some period of time 
using blood glucose (BG) concentration and insulin and 
nutrition administration data. Errors in blood glucose 
concentration and measurement timing can thus affect the 
identified values of SI. 
In the busy intensive care unit (ICU) environment, BG 
measurements are rarely taken and recorded at an exact, 
scheduled time. Sensor errors add uncertainty to the 
measured BG concentration. Both errors propagate through to 
SI during parameter identification, which in turn may impact 
subsequent analyses or glycaemic variability during control. 
Typical point-of-care glucometers have measurement errors 
in the range 2-10% (Abbott, 2010, Arkray, 2007, Roche, 
2007, Roche, 2008, Solnica et al., 2003). The glucometer 
used in the Christchurch Hospital ICU (Super-Glucocard II, 
Arkray Inc., Japan) typically has an error of less than 10% 
(Arkray, 2007). The uncertainty in BG concentration 
resulting from sensor error impacts the identified values of SI 
through altering the glucose flux that must be balanced by the 
insulin-mediated glucose disposal term in the glucose-insulin 
system model. 
The objective of this investigation was to assess the impact of 
both measurement timing and sensor errors on identified 
  
     
values of SI and its hour-to-hour variability. Specifically, the 
SI parameter from a glucose-insulin system model similar to 
that described by Lin et al. (2011) was investigated with 
patient data from the Christchurch Hospital ICU. 
 
2. SUBJECTS AND METHODS 
2.1 Patients 
This study was conducted as retrospective analyses of data 
from 270 patients admitted to the Christchurch Hospital ICU 
between 2005 and 2007. All patients were on the SPRINT 
protocol for at least 24 hours (Chase et al., 2008). Table 1 
shows a summary of the cohort details. The Upper South 
Regional Ethics Committee, New Zealand granted approval 
for the audit, analysis and publication of this data. 
 
Table 1. Cohort details summary. Data are shown as median 
[interquartile range] where appropriate. 
N 270 
Age (years) 65 [49-73] 
Gender (M/F) 165/105 
Operative/Non-Operative 104/166 
Hospital mortality (%) 27% 
APACHE II score 19 [16-25] 
APACHE II ROD (%) 30 [17-53] 
Diabetic status (T1DM/T2DM) 10/34 
ICU length of stay (hrs) 160 [77-346] 
 
2.2 Model-based insulin sensitivity 
The glucose-insulin system model used in this study was an 
enhanced version of the ICING model described by Lin et al. 
(2011), with a new endogenous insulin secretion sub-model 
(7) derived from data not yet published. The model is defined 
below in (1)-(7). Model parameters, rates and constants were 
generally as described in Lin et al. (2011), except for nI, nC  
and VI which have been adjusted to 0.06 min-1, 0.06 min-1 and 
4.0 L, respectively. These changes were made based on an 
analysis of results from several microdialysis studies and the 
population parameters from Van Cauter et al. (1992). 
Endogenous insulin secretion was modelled as a function of 
BG. Sub-model parameters, umin and umax are 16.7 mU.min-1 
and 266.7 mU.min-1, respectively. For non-diabetic patients, 
k1 and k2 take the values 14.9 mU.L.mmol-1.min-1 and -49.9 
mU.min-1. 
The model was implemented in MATLAB (2011b, Natick, 
MA), and a value of SI identified each hour for every patient 
using clinical BG, insulin and nutrition records. The 
parameter identification was performed using an integral 
method that ensured the global optimum value was located 
(Hann et al., 2005). Hour-to-hour SI variability is defined in 
(8). 
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The model-based insulin sensitivity parameter (SI) has been 
shown to correlate well with the insulin sensitivity index 
(ISI) determined by the gold-standard euglycaemic-
hyperinsulinaemic clamp (r >0.90) (Lotz et al., 2008).  
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2.3 BG sensor error 
The point-of-care glucometer used in the Christchurch 
Hospital ICU is the Arkray  Super-Glucocard II (Arkray Inc., 
Japan). Sensor bias was determined from the correlation data 
reported for the glucometer test strips, (Arkray, 2007) and 
was therefore known at all BG concentrations. Precision was 
reported as a coefficient of variation (CV) at three BG 
concentrations, 4.3, 6.9 and 21.0 mmol/L. For this analysis, 
the CV was linearly interpolated for BG concentrations 
within the reported range and held constant outside this 
range. These data were used to construct an additive error 
model for the glucometer used in this investigation. Table 2 
presents the bias and precision components for a range of 
glycaemia. 
  
Table 2. Error components of the Arkray Super-Glucocard II 
glucometer (Arkray, 2007). 
Blood 
glucose 
(mmol/L) 
2.0 4.3 6.9 10.0 21.0 30.0 
Bias (%) +7.9 +2.1 +0.2 -0.8 -2.0 -2.3 
Precision, 
CV (%) 3.5 3.5 2.8 2.8 2.7 2.7 
  
     
The data used in the study was collected by trained clinical 
staff, minimising the potential for additional error through 
device misuse (Bergenstal, 2008). Blood samples tested were 
typically arterial, although, when an arterial line was not 
present, capillary blood was used.  
 
2.4 Timing error 
Measurements and interventions during the SPRINT protocol 
were 1 or 2-hourly and intended to be taken on the hour. 
These measurements were recorded by hand and attributed to 
the nearest hour on the standard paper 24-hour charts used in 
the Christchurch Hospital ICU. Hence, any discrepancies 
between the actual measurement time and the ‘nearest hour’ 
were lost. 
Recent pilot trials of the STAR (Stochastic TARgeted) 
protocol at Christchurch Hospital ICU (Evans et al., 2011) 
provide data to generate a timing error model (1651 
measurements on 20 patients). The STAR protocol is 
implemented on a tablet computer, thus the exact time when 
BG measurements are entered is recorded and can be 
compared to the written records. Using the discrepancies 
between scheduled and actual BG measurements, a model of 
timing error can be generated and applied to data from the 
SPRINT protocol. Although the STAR protocol differs from 
SPRINT, particularly with its computerised interface, it is 
used by the same clinical staff, in the same unit. Hence, it 
may be assumed that timing errors in making measurements 
will be similar. 
Timing errors were limited to a maximum of 20 minutes. The 
empirical error distributions are shown in Figure 1. Errors 
from these distributions were applied additively to the 
SPRINT data by randomly sampling from the error vectors. 
The errors were applied to both the measurement and 
intervention timing. Thus, the measurements and 
interventions remained synchronised, as they would in the 
hospital.  
 
 
Figure 1. Timing error models based on data from the STAR 
pilot trials (Evans et al., 2011). Errors from 1- and 2 hour 
measurements are shown on the left and right, respectively. 
 
 
2.5 Analyses 
To assess the effects of random timing and sensor errors on 
SI, Monte Carlo simulations were performed.  The SI profile 
of each patient in the cohort was refitted n = 100 times with 
randomly sampled errors applied to the observed timing and 
BG concentrations. The SI profiles identified without 
additional random errors were considered the ‘true’ profiles, 
and the Monte Carlo profiles were compared to these to 
assess the impact each of the sources of error, both 
individually and combined. Comparisons of both SI level and 
hour-to-hour variability were made. 
To facilitate comparisons when timing errors were applied, SI 
was identified in 60-minute intervals, rather than between BG 
measurements. This use of fixed, 60-minute fitting intervals 
is consistent with the methodology used for glycaemic 
control by the STAR protocol. 
To analyse the impact of errors on the identified SI level, the 
variation induced by the simulated errors at each hour was 
assessed across the Monte Carlo simulations. To characterise 
the distribution of percentage differences in SI level at each 
hour, between the true and simulated profiles, the width of 
the interquartile range (IQR) was used. Figure 2 illustrates 
the methodology for SI level comparisons between the n = 
100 Monte Carlo simulations and the true data.  
 
 
Figure 2. SI level comparison method for the Monte Carlo 
simulations with added sensor and timing error. The width of 
the interquartile range of differences was used to characterise 
the variability in level induced by the errors. 
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This analysis method resulted in one ‘IQR width’ per patient 
hour. For the 270 patient SPRINT cohort, there were 
approximately 43,000 hours of data. These 43,000 IQR 
widths were presented as cumulative distributions to show 
the overall effect of the errors on the cohort. 
The hour-to-hour variability of simulated data could not be 
compared to the true variability using ratios, as the centre of 
the variability distribution for any given patient was 
approximately zero. Therefore, many values were close to 
zero, causing comparison ratios to approach zero or infinity, 
providing an effectively meaningless metric. To quantify the 
variability of hour-to-hour variability caused by the errors, 
the width of the IQR across the simulations for each hour was 
used. This method relies on the assumption that the median 
value across the simulations for each hour is close to zero. 
A link to the actual variability is provided by the distribution 
of ‘∆Median SI.’ For any given hour, this metric is defined as 
the difference between the median hour-to-hour variability 
(%), across the n simulations, and the actual value (%). 
Typically, the distribution was tightly centred about zero, 
justifying the use of simulation IQR width without explicit 
reference to the actual variability. 
 
3. RESULTS & DISCUSSION 
3.1 Timing error 
Figure 3 shows the impact of timing errors on identified SI 
level (left panel) and variability (right panels). For 95% of 
hours, the IQR width of SI level was less than 12.4%. Thus, 
for those 40,000 hours, half the simulations resulted in SI 
values within approximately ±6.2% of the true value, 
assuming a symmetrical distribution. Similarly, for 
variability, 95% of hours had an IQR width of hour-to-hour 
changes of less than 17.8%, or ±8.9% about the simulation 
median. The top right panel of Figure 3 shows the simulation 
median was typically very close to the true value for 
variability, justifying the assumptions made. 
 
Figure 3. The impact of timing error on SI level (left panel) 
and hour-to-hour variability (right panels), determined by 
Monte Carlo simulation. The panels on the right show the 
location of the median simulated hour-to-hour variability, 
compared to the actual (top) and the variability about that 
median (bottom).  
 
These results show that typical timing errors in isolation have 
relatively small impact on the level and variability of SI. With 
a median absolute difference between the simulated and 
actual measurement intervals of 9 minutes and using bolus 
insulin delivery, this result is not too surprising. Unlike 
infused insulin, bolus delivery ensures that the entire 
prescribed dose is always administered, regardless of the time 
between measurements. In addition, timing discrepancies 
only affect the later parts of the interstitial insulin profile, 
where concentrations are lowest and thus contribute least to 
the area under the curve used in fitting the SI parameter 
(Hann et al., 2005). 
 
3.2 BG sensor error 
Figure 4 shows the impact of BG sensor errors on SI level 
(left panel) and variability (right panels). The variability 
induced in both SI level and variability is greater than that 
due to timing error. The increases at the median values for 
level and variability compared to timing error of Figure 3 
were 4.9% and 2.2%, respectively (p = 0, Wilcoxon rank-sum 
test). However, with so many data points, a statistically 
significant difference is almost guaranteed.  
 
Figure 4. The impact of BG sensor error on SI level (left 
panel) and hour-to-hour variability (right panels), determined 
by Monte Carlo simulation. The panels on the right show the 
location of the median simulated hour-to-hour variability, 
compared to the actual (top) and the variability about that 
median (bottom). 
 
The non-zero minimum width of SI level IQR evident in the 
left panel of Figure 4 is the result of the sensor bias. This 
minimum width of 2.7% was not present with the zero-mean 
timing error simulations of Figure 3, or if the bias is set to 
zero (results not shown). 
 
3.3 Combined measurement error 
Figure 5 shows the impact of the combined timing and BG 
sensor errors on SI level (left panel) and variability (right 
panels). The previous two sections have characterised the 
individual contributions of timing and sensor error. This 
analysis combines them, simulating errors seen in the real, 
clinical situation.  
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For 95% of hours, the IQR width of SI level was less than 
23.9%. Thus, assuming a symmetrical distribution, half the 
simulations resulted in SI values within approximately ±12% 
of the true value. Similarly for variability, the 95th percentile 
was 34.9%, indicating that for half the simulations the hour-
to-hour variability of SI was within ±17.5%. 
 
Figure 5. The impact of combined timing and BG sensor 
error on SI level (left panel) and hour-to-hour variability 
(right panels), determined by Monte Carlo simulation. The 
panels on the right show the location of the median simulated 
hour-to-hour variability, compared to the actual (top) and the 
variability about that median (bottom). 
 
3.4 Implications of results 
The clinical impact during glycaemic control of changes to SI 
level induced by sensor and timing errors is likely to be 
limited. Identified values of SI were typically within 12% of 
the true value when influenced by both sources of error. In 
contrast, changes in SI greater than 20% were seen with 
glucocorticoid treatment (Pretty et al., 2010) and improving 
patient condition over the first 18 hours of ICU stay (Pretty et 
al., 2012).  
A second, potentially clinically significant, impact is on 
analytical use of SI as a marker of injury or change in state.  
Much of the true hour-to-hour change of this SPRINT cohort 
was smaller than the variability induced by sensor and timing 
errors. The IQR of true hour-to-hour variability across the 
entire cohort was -9.7% to 13.9% and 63% of all values lay 
in the range ±17.5%. Thus, short-term changes in SI may be a 
result of measurement timing or sensor errors rather than a 
true physiological phenomenon. Hence, using changes in SI 
level as a diagnostic must be done with caution, potentially 
looking at longer-term trends, where the effects of random 
errors may be cancelled by averaging over time. 
In the context of the STAR protocol, the increase in hour-to-
hour variability may be clinically significant. STAR uses a 
stochastic model of expected SI hour-to-hour variability to 
forecast the results of potential interventions and avoid 
hypoglycaemia. The relatively large, ±17.5%, range of hour-
to-hour variability about the median caused by errors, 
suggests that a significant proportion of this expected 
variability may be dominated by these errors, rather than 
physiological variability. Hence, to reduce the impact of 
these errors, the 5-95 range of the stochastic model should be 
used. SI values at these more extreme percentiles are less 
likely to be influenced by random sensor or timing errors. 
 
3.5 Potential for reducing error 
There is no effective way to reduce the impact of these errors 
as they are random and apply equally to all patients. The only 
available option is to reduce the magnitude of the errors. The 
timing error distribution shown in Figure 1 shows that more 
than 85% of measurements are within 10 minutes of the 
scheduled time, which is a very good result in a busy ICU 
environment. In contrast, BG sensor errors can be reduced 
with better, more accurate, but likely more expensive 
equipment.  
To compare the impact of sensor errors from glucometers 
with a state of the art blood gas analyser (BGA), an error 
model was developed for the Bayer RapidLab 860 (Bayer 
Diagnostics, Tarrytown, NY) (2004, Peet et al., 2002). Errors 
for this BGA consist of very little bias (≤ 0.06 mmol/L) and 
CV in the range 1.7%-4.9%, depending on BG concentration. 
The RapidLab 860 is used in the Christchurch Hospital 
Neonatal ICU (Le Compte, 2009), and thus represents a 
realistic option for the adult ICU in Christchurch. An n = 50 
run Monte Carlo simulation was performed with both timing 
and BG sensor errors from the BGA for a basic comparison. 
The results show only a minor improvement by using the 
BGA.  The 95th percentile of IQR widths reduced from 23.9% 
to 21.0% and from 34.9% to 30.2% for level and variability, 
respectively. These results appear surprising, but are probably 
due to the relatively low reported errors of the glucometer. 
Data for the error model was taken from the manufacturer’s 
data-sheet (Arkray, 2007). However, a published report 
(Solnica and Naskalski, 2005) failed to recreate these results, 
possibly due to user error, sample type, abnormal hematocrit 
or interfering substances (Bergenstal, 2008).  
 
4. CONCLUSION 
The objective of this study was to assess and quantify the 
impact of typical timing and BG sensor errors on the level 
and variability of model-based SI. Specifically, the variability 
of level and the variability of SI hour-to-hour variability were 
investigated under the influence of these sources of error, 
both separately and combined. Measurement timing errors 
were shown to have a relatively small impact on the SI 
parameter. The BG concentration errors of the Arkray 
glucometer had a larger effect on SI and tended to dominate 
the combined analysis. 
The results of this study indicate that the impact of errors on 
SI level is unlikely to be clinically significant and probably 
overshadowed by physiological or therapy factors arising 
from the critical condition of the patients. In contrast, the 
impact of errors on hour-to-hour SI variability is more 
pronounced and may impact the way the SI parameter is 
utilised for control and analysis. 
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This analysis indicated that for a given SI level, variability 
induced by errors might dominate the IQR of the probability 
density function describing SI for the subsequent hour. 
Hence, to avoid inadvertently basing control decisions on this 
artificial variability, the 5-95 percentile range of the 
stochastic model should be used. In addition, using changes 
in SI level as a diagnostic must be done with caution, 
potentially looking at longer-term trends, where the effects of 
random errors may be cancelled by averaging over time. 
Given the random nature of these errors, the only feasible 
method of mitigation is to use BG sensors with smaller 
errors. However, a comparison with results from a state of the 
art, clinical blood gas analyser showed that the limited 
improvement in performance probably doesn’t justify the 
significantly increased cost of the device. However, 
understanding the effect of sensor and timing errors on SI 
allows their impact to be taken into account when using the 
parameter for control and analysis. 
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